Reddy points to coverage cuts in Maine and Michigan and cites a study estimating $192,735 in lifetime medical savings for GLP-1 users aged 40 to 50.
Recap by typeshit. Full story at Medical Economics.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
A survey presented at the EADV 2026 Congress found more nail lifting and color changes in GLP-1 users, but the link weakened after adjustments.
A post on the trial pitting Lilly's tirzepatide against dulaglutide for cardiovascular outcomes in people with type 2 diabetes.
Loading…